RCRashikh Ahmed Choudhury

Rashikh Ahmed Choudhury

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rashikh Ahmed Choudhury has a total of 241 co-authors. Here are the top co-authors by number of shared publications:

  • Trevor L. Nydam

    Division of Transplantation, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA

    14 shared publications
  • Hunter B. Moore

    Division of Transplantation, Department of Surgery, University of Colorado Hospital, Aurora, CO, USA

    8 shared publications
  • Dor Yoeli

    Department of Surgery, University of Colorado School of Medicine, Aurora, CO, 80045, USA

    7 shared publications
  • Megan A. Adams

    Division of Transplant Surgery, Department of Surgery Children's Hospital Colorado, University of Colorado Anschutz Medical Campus Aurora Colorado USA

    7 shared publications
  • Kristoffel R. Dumon

    Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

    6 shared publications
  • Elizabeth A. Pomfret

    Division of Transplantation, Department of Surgery University of Colorado School of Medicine Aurora Colorado USA

    5 shared publications

Latest Publications

  • Outcomes after robotic and open kidney transplant: A propensity score-matched analysis

    by Haaris Kadri, Rossana Maffei, Ryan Dang, Keith Hansen, Dor Yoeli, Marissa Di Napoli, Cassidy Yoshida, Ivan Rodriguez, Carlos Gonçalves, Shannon Lyons, et al.


  • Open Access

    Robotic Kidney Transplantation With Grafts With Multiple Arteries: A Single-center Experience and Outcome Analysis

    by Rossana Maffei, Haaris Kadri, Andrii Khomiak, Keith Hansen, Dor Yoeli, Wells B. LaRiviere, Shannon Lyons, Sixto Giusti, Terri Montague, James Cooper, et al.

    Background.: Although robotic kidney transplantation (RKT) is an emerging minimally invasive surgical technique, graft anatomical variations such as multiple renal arteries (MRAs) remain a perceived limitation to its broader dissemination. This study evaluates the feasibility and short-term outcomes of RKT in grafts with MRAs compared with single renal artery (SRA) grafts. Methods.: We conducted a retrospective review of RKT procedures performed at a single center from November 2021 to January 2026. Perioperative and postoperative outcomes were compared between MRA and SRA cohorts. A subanalysis was performed within the MRA group to assess the impact of single versus multiple arterial anastomoses. All RKTs were performed using the Da Vinci Xi system. Results.: In the assessed period, 126 robotic-assisted kidney transplants were performed: 94 with SRA (74.6%) and 32 with MRAs (25.4%). Across the overall cohort, 1 patient (0.8%) had their operation converted to an open procedure. Total operative time had a median duration of 257 min (interquartile range [IQR], 213.0–309.8) in the SRA cohort compared with 303 min (IQR, 269.2–355.2) in the MRA cohort ( P =  0.004). Warm ischemia time was measured at 34 min (IQR, 29.0–42.0) in the SRA group and at 40 min (IQR, 33.0–45.2) in the MRA group ( P =  0.013). Within the MRA cohort, 9 grafts (28.1%) required a single arterial anastomosis (SAA) and 23 (71.9%) required multiple arterial anastomoses (MAA). The median operative time was 270 min (IQR, 210.0–305.0; SAA) versus 313 min (IQR, 283.5–392.5; MAA, P =  0.033). Warm ischemia time, anastomosis time, blood loss, length of stay, delayed graft function, serum creatinine at 1 mo, and graft survival did not differ between SAA and MAA cohorts. Conclusions.: RKT using grafts with MRAs is technically feasible and yields perioperative and short-term outcomes comparable with those of SRA grafts. The presence of MRAs should not be considered a contraindication to robotic transplantation.


  • Open Access

    Safety in Robotic Kidney Transplant for All-Comers

    by Haaris Kadri, Rossana Maffei, Keith Hansen, Dor Yoeli, Marissa Di Napoli, Cassidy Yoshida, Shannon Lyons, Sixto Giusti, Terri Montague, James Cooper, et al.

    Key Points: Robotic kidney transplantation demonstrates equivalent perioperative safety across body mass index strata, including body mass index ≥40 kg/m 2 . High body mass index alone was not associated with higher surgical complexity, delayed graft function, or early graft loss. Robotic kidney transplant may expand equitable access to transplantation by mitigating traditional obesity-related surgical risks. Background: Obesity remains a common barrier to kidney transplantation, with many centers enforcing strict body mass index (BMI) cutoffs because of concerns regarding surgical complexity and postoperative complications. Robotic kidney transplantation (RKT) has emerged as a minimally invasive alternative that may mitigate obesity-associated surgical risks. However, outcomes across granular BMI subgroups, particularly among patients with morbid obesity (BMI ≥40 kg/m 2 ), remain incompletely characterized. Methods: We performed a retrospective cohort study of adult patients undergoing RKT at a single academic transplant center between November 2021 and September 2025. Patients were stratified by BMI into two primary cohorts (BMI 2 ) with a secondary subgroup analysis comparing those with BMI 30–40 versus ≥40 kg/m 2 . Demographic characteristics, intraoperative metrics, and 30-day postoperative outcomes were compared. Results: A total of 104 patients underwent RKT, with 26 patients with BMI 2 , 53 with BMI between 30 and 40 kg/m 2 , and 25 with BMI ≥40 kg/m 2 . No significant differences were observed between BMI P = 0.03). In subgroup analysis, patients with BMI ≥40 demonstrated comparable intraoperative parameters and postoperative complication rates to those with BMI 30–40, with no significant differences in graft or patient survival. Conclusions: RKT is associated with comparable perioperative outcomes across BMI categories, including among patients with morbid obesity. These findings challenge rigid BMI-based exclusion criteria and support a more individualized approach to transplant candidacy in the era of robotic surgery.


  • Open Access

    Elevations in Donor-Derived Cell-Free DNA and Allograft Outcomes in Kidney Transplantation

    by Jeffrey A. Klein, David Taber, David Wojciechowski, Didier A. Mandelbrot, Renata Glehn-Ponsirenas, Oyedolamu Olaitan, Pranjal Jain, James Lu, Martina M. McGrath, Mohanram Narayanan, et al.

    Key Points: We assessed whether an initial donor-derived cell-free DNA elevation during routine surveillance was associated with allograft dysfunction and loss in kidney transplant recipients. Intermediate and high donor-derived cell-free DNA states were independently associated with 3.7-fold and 6.4-fold higher risks of allograft loss, respectively. Persistently low donor-derived cell-free DNA levels were associated with low rates of rejection and allograft loss, identifying a low-risk population. Background: Although donor-derived cell-free DNA (dd-cfDNA) correlates with histologic rejection and injury severity, its association with long-term graft outcomes has yet to be well established in kidney transplant recipients. We hypothesize that among patients monitored with dd-cfDNA, an initial elevation may be associated with subsequent allograft dysfunction and loss. Methods: The Kidney Allograft Outcomes AlloSure Registry is a prospective, multicenter cohort of 1743 adult kidney transplant recipients from 56 US centers; this analysis included 1258 patients who initiated dd-cfDNA surveillance 15–60 days post-transplant with up to 3-year follow-up. A multistate model was applied to characterize transitions from a low dd-cfDNA state (no elevations) to intermediate (0.5%–1.0% with ≥61% relative change value) or high (≥1.0%) dd-cfDNA states, and their unadjusted and covariate-adjusted associations with allograft loss or all-cause death were quantified using hazard regression models. Results: Within 3 years, 36% of patients transitioned to an elevated dd-cfDNA state (intermediate n =216; high n =233). Allograft dysfunction by 36 months occurred significantly more often in patients with dd-cfDNA elevations despite preserved allograft function at the time of elevation (eGFR ≥60 ml/min per 1.73 m 2 in 42% of intermediate and 33% of high), consistent with subclinical injury. Transitions from low to elevated dd-cfDNA states were strongly associated with subsequent allograft loss (adjusted hazard ratios, 3.70 [95% confidence interval [CI], 1.38 to 9.90] for intermediate; 6.36 [95% CI, 2.80 to 14.42] for high), while mortality did not differ by dd-cfDNA state. Conclusions: Initial dd-cfDNA elevations exceeding established thresholds were independently associated with higher risks of allograft dysfunction and loss across both elevation categories, whereas patients who remained in the low dd-cfDNA state experienced favorable outcomes.


  • Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis

    by Marissa Di Napoli, Kelly Morton, Cole Evensky, Cassidy Yoshida, Maria Baimas-George, Rose Castle, Peter Kennealey, Trevor Nydam, Rashikh Choudhury


  • Sleeve gastrectomy versus GLP-1 agonist to improve kidney transplant access in end-stage renal disease patients with obesity: a decision analysis

    by Marissa Di Napoli, Armaun D. Rouhi, Kristoffel R. Dumon, Rose Castle, Noel N. Williams, Maria Baimas-George, Peter T. Kennealey, Trevor L. Nydam, Rashikh A. Choudhury


  • Open Access

    Thoracoabdominal Normothermic Regional Perfusion: Real-world Experience and Outcomes of DCD Liver Transplantation

    by Yanik J. Bababekov, Anna H. Ba Ha, Trevor L. Nydam, Carlos Goncalves, Rashikh Choudhury, JoLynn PA-C Shinsako, Maria Baimas-George, David M. Reynolds, Cassidy Ba Yoshida, Caroline A. Racke, et al.

    Background.: Donation after circulatory death liver transplantation (DCD LT) is underused given historical outcomes fraught with ischemic cholangiopathy (IC). We aimed to assess 6-mo IC in LT from DCD via normothermic regional perfusion (NRP) compared with DCD via static cold storage (SCS). Methods.: A retrospective review of adult Maastricht-III DCD liver donors and recipients at the University of Colorado Hospital from January 1, 2017, to August 27, 2024, was performed. The 6-mo IC rate was compared between NRP and SCS. Secondary outcomes included biochemical assessments of accepted versus declined NRP liver allografts and allograft and patient survival for NRP and SCS groups. Results.: One hundred sixty-two DCD LTs (SCS = 79; NRP = 97) were performed and 150 recipients (SCS = 74; NRP = 86) reached 6-mo follow-up. Six-month IC was lower for NRP compared with SCS (1.2% versus 9.5%, P = 0.03). The Donor Risk Index (2.44 [2.02–2.82] versus 2.17 [1.97–2.30], P = 0.002) and UK DCD Risk Score (4.2 ± 2.9 versus 3.2 ± 2.3, P = 0.008) were higher for NRP versus SCS. The Liver Graft assessment Following Transplantation score was less for NRP compared with SCS (–3.3 versus –3.1, P < 0.05). There were several differences in median biochemical parameters during NRP between accepted and declined livers, including higher terminal biliary bicarbonate (22.7 [20.9–29.1] versus 10.8 [7.6–13.1] mEq/L, P = 0.004). There were no significant differences in 12-mo allograft or patient survival for NRP versus SCS. Conclusions.: NRP is a disruptive innovation that improves the utilization of DCD livers. Despite higher-risk donor-recipient pairing for NRP compared with SCS, we demonstrate a decrease in IC for NRP. These data facilitate benchmarking of thoracoabdominal NRP DCD LT and support further protocol development.


  • Prognostic value of body mass index is highly modified by sex among recipients of liver transplant

    by Micaella R. Zubkov, Hunter B. Moore, Rocio Lopez, Deena Brosi, Rashikh A. Choudhury, Susana Arrigain, Jessica Saben, Kendra D. Conzen, James J. Pomposelli, Elizabeth A. Pomfret, et al.

    An abstract is unavailable. This article is available as a PDF only.


  • Uncontrolled donation after cardiac death kidney transplantation: Opportunity to expand the donor pool?

    by Armaun D. Rouhi, Rashikh A. Choudhury, Gerard D. Hoeltzel, Kas Prins, Dor Yoeli, Hunter B. Moore, Noel N. Williams, Kristoffel R. Dumon, Trevor L. Nydam


  • Can non‐directed living liver donation help improve access to grafts and correct socioeconomic disparities in pediatric liver transplantation?

    by Dor Yoeli, Amy G. Feldman, Rashikh A. Choudhury, Hunter B. Moore, Shikha S. Sundaram, Trevor L. Nydam, Michael E. Wachs, Elizabeth A. Pomfret, Megan A. Adams, Whitney E. Jackson

    Background: Each year, children die awaiting LT as the demand for grafts exceeds the available supply. Candidates with public health insurance are significantly less likely to undergo both deceased donor LT and D‐LLD LT. ND‐LLD is another option to gain access to a graft. The aim of this study was to evaluate if recipient insurance type is associated with likelihood of D‐LLD versus ND‐LLD LT.Methods: The SRTR/OPTN database was reviewed for pediatric LDLT performed between January 1, 2014 (Medicaid expansion era) and December 31, 2019 at centers that performed ≥1 ND‐LLD LDLT during the study period. A multivariable logistic regression was performed to assess relationship between type of living donor (directed vs. non‐directed) and recipient insurance.Results: Of 299 pediatric LDLT, 46 (15%) were from ND‐LLD performed at 18 transplant centers. Fifty‐nine percent of ND‐LLD recipients had public insurance in comparison to 40% of D‐LLD recipients (p = .02). Public insurance was associated with greater odds of ND‐LLD in comparison to D‐LLD upon multivariable logistic regression (OR 2.37, 95% CI 1.23–4.58, p = .01).Conclusions: ND‐LLD allows additional children to receive LTs and may help address some of the socioeconomic disparity in pediatric LDLT, but currently account for only a minority of LDLT and are only performed at a few institutions. Initiatives to improve access to both D‐LLD and ND‐LLD transplants are needed.